Keyphrases
Active Therapy
20%
Adverse Reactions
20%
Age at Initiation
20%
Change from Baseline
20%
Child Age
20%
Continuation Treatment
20%
DBPCFC
20%
Desensitization
100%
Dose Change
20%
Epicutaneous Immunotherapy
100%
Extended Treatment
20%
Food Allergy
100%
IgG4-related Disease (IgG4-RD)
20%
Local Patch
20%
Peanut
80%
Peanut Allergy
100%
Peanut Protein
20%
Placebo
80%
Predictive Success
20%
Randomized Controlled Trial
20%
Safety Self-efficacy
20%
Site Reaction
20%
Treatment Efficacy
20%
Viaskin Peanut
80%
Young Age
20%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
11%
Desensitization
55%
Food Allergy
100%
Immunoglobulin G4
11%
Immunotherapy
100%
Peanut
100%
Peanut Allergy
100%
Placebo
55%
Randomized Controlled Trial
11%
Transdermal Patch
44%
Immunology and Microbiology
Food Allergy
100%
Immunoglobulin G4
25%
Immunotherapy
100%
Peanut Allergy
100%